DAVID PURSELLE: Open Payments
NPI 1356384135 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$80,699 in 132 payments from 12 companies in 2025. Trend: 2023 $91,827 · 2024 $57,152 · 2025 $80,699
Consulting: $41,877Speaker / faculty: $23,817Travel & lodging: $11,827Food & beverage: $3,178
| Company | Payments | Amount |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 51 | $53,941 |
| ABBVIE INC. | 18 | $12,641 |
| Vanda Pharmaceuticals Inc. | 21 | $11,288 |
| Neurocrine BioSciences, Inc. | 13 | $2,151 |
| Janssen Pharmaceuticals, Inc | 7 | $181 |
| Otsuka America Pharmaceutical, Inc. | 11 | $163 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $131 |
| Lundbeck LLC | 1 | $102 |
| Axsome Therapeutics, Inc. | 2 | $40 |
| Tris Pharma Inc | 1 | $24 |
Products named: REXULTI, VRAYLAR, FANAPT, SPRAVATO, CAPLYTA, HETLIOZ, Auvelity, Dyanavel XR.
Industry payments across GA — which companies pay providers there.
